Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
AMINOSYN II 10% vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and nitrogen balance maintenance in patients unable to tolerate adequate oral/enteral intake.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
Intravenous infusion: 500 mL to 1 L of 10% solution (50-100 g amino acids) per day, administered at a rate not exceeding 100 mL/h. Typical initial dose: 0.8-1.5 g/kg/day of amino acids, adjusted based on metabolic needs and tolerance.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
Variable depending on metabolic state; for individual amino acids, half-lives range from 10 to 100 minutes. In renal impairment, accumulation can occur. No single terminal half-life for the mixture.
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Primarily renal as amino acids and metabolites; >90% of infused amino acids are reabsorbed by proximal tubules, with less than 10% excreted unchanged in urine. Biliary/fecal excretion negligible.
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution